<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neth Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Neth Heart J</journal-id><journal-title-group><journal-title>Netherlands Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">1568-5888</issn><issn pub-type="epub">1876-6250</issn><publisher><publisher-name>BSL Media &#x00026; Learning</publisher-name><publisher-loc>Houten</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40293703</article-id><article-id pub-id-type="pmc">PMC12098227</article-id>
<article-id pub-id-type="publisher-id">1954</article-id><article-id pub-id-type="doi">10.1007/s12471-025-01954-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Prevalence of transthyretin amyloid cardiomyopathy in an unselected cohort with heart failure with preserved ejection fraction</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0005-0763-7551</contrib-id><name><surname>Achten</surname><given-names>Anouk</given-names></name><address><email>anouk.achten@mumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>van Empel</surname><given-names>Vanessa P. M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Weerts</surname><given-names>Jerremy</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mourmans</surname><given-names>Sanne</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Brunner-La Rocca</surname><given-names>Hans-Peter</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sanders-van Wijk</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Knackstedt</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02d9ce178</institution-id><institution-id institution-id-type="GRID">grid.412966.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0480 1382</institution-id><institution>Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), </institution><institution>Maastricht University Medical Centre (MUMC+), </institution></institution-wrap>Maastricht, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03bfc4534</institution-id><institution-id institution-id-type="GRID">grid.416905.f</institution-id><institution>Department of Cardiology, </institution><institution>Zuyderland Medical Centre, </institution></institution-wrap>Heerlen, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><volume>33</volume><issue>6</issue><fpage>193</fpage><lpage>198</lpage><history><date date-type="accepted"><day>20</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>Heart failure with preserved ejection fraction (HFpEF) represents a&#x000a0;heterogeneous syndrome characterised by various underlying aetiologies, such as transthyretin amyloid cardiomyopathy (ATTR-CM). The aim of this study was to determine the true prevalence of ATTR-CM in a&#x000a0;Dutch all-comers cohort of HFpEF patients.</p></sec><sec><title>Methods</title><p>From 2018 to 2023, all patients diagnosed with HFpEF underwent prospective screening for ATTR-CM. Diagnosis of ATTR-CM was made in accordance with guideline recommendations.</p></sec><sec><title>Results</title><p>Of the 202 HFpEF patients included (mean&#x0202f;&#x000b1;&#x02009;standard deviation age: 76&#x0202f;&#x000b1;&#x02009;7&#x000a0;years; 64% female), 9&#x000a0;(5%) showed cardiac uptake on scintigraphy, of whom 6&#x000a0;(3%) were subsequently diagnosed with wild-type ATTR-CM. Left ventricular wall thickness (LVWT) was significantly higher in ATTR-CM patients than non-amyloid HFpEF patients (median interventricular septum diameter: 15&#x0202f;mm; interquartile range (IQR): 11&#x02013;17 vs 10&#x0202f;mm; IQR: 9&#x02013;11; <italic>p</italic>&#x0202f;&#x0003c;&#x02009;0.001). Interestingly, 2&#x000a0;ATTR-CM patients (33%) did not have increased LVWT at the time of diagnosis. These&#x000a0;2&#x000a0;patients were in a&#x000a0;less advanced prognostic stage.</p></sec><sec><title><italic>Conclusion</italic></title><p>This study revealed a&#x000a0;low prevalence of ATTR-CM (3%) in an unselected HFpEF cohort. We identified ATTR-CM patients without increased LVWT (33%), who presented at an earlier disease stage. Hence, relying exclusively on LVWT for the diagnosis of ATTR-CM may result in delayed and/or missed diagnoses.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Amyloid cardiomyopathy</kwd><kwd>Transthyretin amyloidosis</kwd><kwd>Heart failure with preserved ejection fraction</kwd><kwd>Prevalence</kwd><kwd>Left ventricular wall thickness</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004325</institution-id><institution>AstraZeneca</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014476</institution-id><institution>Pfizer Pharmaceuticals</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Society of Nederlandse Vereniging voor Cardiologie (NVVC) and Springer Media B.V. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>What&#x02019;s new?</title><p>
<list list-type="bullet"><list-item><p>To our knowledge, this is the first study that screened an unselected cohort of patients with heart failure with preserved ejection fraction (HFpEF) to determine the true prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM).</p></list-item><list-item><p>Previous studies exclusively included HFpEF patients with an increased left ventricular wall thickness, potentially overlooking those in an early disease stage without such left ventricular hypertrophy.</p></list-item><list-item><p>Early diagnosis of ATTR-CM is imperative as current treatments only mitigate amyloid formation and disease progression rather than achieve complete cessation.</p></list-item></list>
</p></sec><sec id="Sec1"><title>Introduction</title><p>Heart failure with preserved ejection fraction (HFpEF) represents a&#x000a0;heterogeneous syndrome. Transthyretin amyloid cardiomyopathy (ATTR-CM) has been identified as a&#x000a0;cause of HFpEF, with reported prevalences rates ranging from 5 to 25% [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. Diagnosing ATTR-CM early is imperative, as current treatments only mitigate amyloid formation and disease progression rather than achieve complete cessation [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Currently, ATTR-CM is suspected in HFpEF patients when left ventricular wall thickness (LVWT) &#x02265;&#x0202f;12&#x0202f;mm [<xref ref-type="bibr" rid="CR7">7</xref>]. However, recent studies have indicated that manifestations of amyloid deposition appear years before ATTR-CM is diagnosed [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. These early manifestations highlight the fact that ATTR-CM is a&#x000a0;slowly progressive disease, with increased LVWT appearing at a&#x000a0;later disease stage [<xref ref-type="bibr" rid="CR10">10</xref>]. Detection of ATTR-CM prior to the onset of LV hypertrophy could provide an opportunity for therapeutic interventions to halt disease progression in its early stages by preventing further amyloid deposition.</p><p>Previous studies have predominantly included HFpEF patients with increased LVWT [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], potentially overlooking those in an early disease stage without such LV hypertrophy [<xref ref-type="bibr" rid="CR10">10</xref>]. To determine the true prevalence of ATTR-CM, we systematically screened an all-comers HFpEF population for ATTR-CM, irrespective of LVWT (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Infographic of prevalence of transthyretin cardiac amyloidosis in an unselected heart failure with preserved ejection fraction cohort. (Created with BioRender)</p></caption><graphic xlink:href="12471_2025_1954_Fig1_HTML" id="d33e265"/></fig></p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p>From 2018 to 2023, all HFpEF patients attending a&#x000a0;specialised HFpEF outpatient clinic were prospectively screened for ATTR-CM. This HFpEF outpatient clinic was set up to systematically diagnose HFpEF in patients referred for symptoms of this disease. Most patients referred to the clinic had previously undergone echocardiography demonstrating a&#x000a0;preserved LV ejection fraction (LVEF), raising suspicion of HFpEF. Only patients subsequently diagnosed with HFpEF were included in this study. HFpEF diagnosis was based on the 2016 European Society of Cardiology definition. Exclusion criteria included prior evaluation for amyloid cardiomyopathy, LVEF &#x0003c;&#x0202f;50% or unwillingness to participate. Written informed consent was obtained from all included patients, and the local medical ethics review committee approved the study protocol (nr. NL76585.068.21).</p></sec><sec id="Sec4"><title>Screening for transthyretin amyloid cardiomyopathy</title><p>HFpEF patients were screened for ATTR-CM using bone scintigraphy with single-photon emission computerized tomography, as well as serum and urine analysis for protein electrophoresis, immunofixation and light chain quantification&#x000a0;[<xref ref-type="bibr" rid="CR7">7</xref>]. ATTR-CM diagnosis was based on positive bone scintigraphy (<sup>99m</sup>Tc&#x02013;hydroxymethylene diphosphonate; Perugini grade&#x000a0;II or&#x000a0;III) with the absence of monoclonal gammopathy. In inconclusive cases (Perugini grade&#x000a0;I), diagnosis relied on a&#x000a0;positive cardiac biopsy for transthyretin amyloid, in accordance with current guidelines [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Information on the presence of typical cardiac and extracardiac red flags was extracted from medical records, including LVWT &#x02265;&#x0202f;12&#x0202f;mm [<xref ref-type="bibr" rid="CR6">6</xref>], atrial fibrillation [<xref ref-type="bibr" rid="CR11">11</xref>], aortic valve sclerosis with restriction [<xref ref-type="bibr" rid="CR12">12</xref>], unilateral or bilateral carpal tunnel syndrome [<xref ref-type="bibr" rid="CR13">13</xref>], trigger finger [<xref ref-type="bibr" rid="CR14">14</xref>], polyneuropathy [<xref ref-type="bibr" rid="CR15">15</xref>], spinal canal stenosis [<xref ref-type="bibr" rid="CR16">16</xref>], hip or knee arthroplasty [<xref ref-type="bibr" rid="CR17">17</xref>], presence of a&#x000a0;pacemaker [<xref ref-type="bibr" rid="CR18">18</xref>], conduction delay (PQ duration &#x02265;&#x0202f;200&#x0202f;ms or QRS duration &#x02265;&#x0202f;120&#x0202f;ms) or micro-voltage signals on electrocardiography [<xref ref-type="bibr" rid="CR7">7</xref>].</p></sec><sec id="Sec5"><title>Statistical analysis</title><p>Descriptive analyses were conducted to examine and compare demographics, comorbidities, red flags for ATTR-CM, biological data and echocardiographic measurements between patients diagnosed with ATTR-CM and non-amyloid HFpEF patients. Categorical and ordinal variables are presented as number (percentage) and were compared using the Fisher&#x02019;s exact test or Mann-Whitney&#x000a0;U&#x000a0;test, as appropriate. Continuous variables are expressed as mean&#x0202f;&#x000b1;&#x02009;standard deviation (SD) or median and interquartile range (IQR) and were compared using the Mann-Whitney&#x000a0;U&#x000a0;test when applicable. All statistical analyses were performed using RStudio version 2021.09.01 (Boston, MA, USA). A&#x000a0;<italic>p</italic>-value of &#x0003c;&#x0202f;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec6"><title>Results</title><p>This study included 202 consecutive HFpEF patients (mean&#x0202f;&#x000b1;&#x02009;SD age: 76&#x0202f;&#x000b1;&#x02009;7&#x000a0;years; 64% female) (Tab.&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). A&#x000a0;total of 9&#x000a0;HFpEF patients (5%) showed cardiac tracer uptake on bone scintigraphy (Perugini grade &#x02265;&#x0202f;I) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Bone scintigraphy was inconclusive in 4&#x000a0;patients, 2&#x000a0;of whom underwent subsequent endomyocardial biopsy. The other 2&#x000a0;patients chose not to pursue further investigations and were excluded from further analyses. Endomyocardial biopsy confirmed the presence of ATTR-CM in 1&#x000a0;patient, ultimately resulting in a&#x000a0;diagnosis of ATTR-CM in 6&#x000a0;patients (3%) and an inconclusive diagnosis in 2&#x000a0;patients. No TTR gene mutations were found among the patients diagnosed with ATTR-CM. Monoclonal gammopathy was present in 1&#x000a0;ATTR-CM patient, who was subsequently diagnosed with monoclonal gammopathy of unknown significance by a&#x000a0;haematologist, without suspicion of light chain amyloidosis.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Study population (<italic>N</italic>&#x0202f;=&#x02009;202)</th><th>Positive scintigraphy (<italic>n</italic>&#x0202f;=&#x02009;9)</th><th>Non-amyloid HFpEF (<italic>n</italic>&#x0202f;=&#x02009;194)</th><th>ATTR-CM (<italic>n</italic>&#x0202f;=&#x02009;6)</th><th><italic>P</italic>-value</th></tr></thead><tbody><tr><td>Female</td><td>129 (64%)</td><td>&#x02007;&#x02007;&#x02007;2 (22%)</td><td>127 (66%)</td><td>&#x02007;&#x02007;&#x02007;1 (17%)</td><td><bold>&#x02008;&#x02008;&#x02007;0.024</bold></td></tr><tr><td>Age (years)</td><td>&#x02007;76 &#x000b1;&#x0202f;7</td><td>&#x02007;&#x02007;79 [77&#x02013;83]</td><td>&#x02007;77 [72&#x02013;81]</td><td>&#x02007;&#x02007;79 [78&#x02013;82]</td><td>&#x02008;&#x02008;&#x02007;0.226</td></tr><tr><td colspan="6"><italic>Medical history</italic></td></tr><tr><td>&#x02013;&#x000a0;Carpal tunnel syndrome</td><td>&#x02007;24 (12%)</td><td>&#x02007;&#x02007;&#x02007;5 (56%)</td><td>&#x02007;19 (10%)</td><td>&#x02007;&#x02007;&#x02007;4 (67%)</td><td><bold>&#x02008;&#x02008;&#x02007;0.002</bold></td></tr><tr><td>&#x02013;&#x000a0;Polyneuropathy</td><td>&#x02007;22 (11%)</td><td>&#x02007;&#x02007;&#x02007;2 (22%)</td><td>&#x02007;20 (10%)</td><td>&#x02007;&#x02007;&#x02007;2 (33%)</td><td>&#x02008;&#x02008;&#x02007;0.129</td></tr><tr><td>&#x02013;&#x000a0;Spinal canal stenosis</td><td>&#x02007;22 (11%)</td><td>&#x02007;&#x02007;&#x02007;1 (11%)</td><td>&#x02007;21 (11%)</td><td>&#x02007;&#x02007;&#x02007;1 (17%)</td><td>&#x02008;&#x02008;&#x02007;0.510</td></tr><tr><td>&#x02013;&#x000a0;Atrial fibrillation/flutter</td><td>&#x02007;86 (43%)</td><td>&#x02007;&#x02007;&#x02007;7 (78%)</td><td>&#x02007;79 (41%)</td><td>&#x02007;&#x02007;&#x02007;5 (83%)</td><td>&#x02008;&#x02008;&#x02007;0.212</td></tr><tr><td>&#x02013;&#x000a0;Pacemaker</td><td>&#x02007;24 (12%)</td><td>&#x02007;&#x02007;&#x02007;1 (11%)</td><td>&#x02007;24 (12%)</td><td>&#x02007;&#x02007;&#x02007;0 (0%)</td><td>&#x02008;&#x02008;&#x02007;0.129</td></tr><tr><td>&#x02013;&#x000a0;Hypertension</td><td>159 (78%)</td><td>&#x02007;&#x02007;&#x02007;7 (78%)</td><td>153 (79%)</td><td>&#x02007;&#x02007;&#x02007;4 (67%)</td><td>&#x02008;&#x02008;&#x02007;0.604</td></tr><tr><td>&#x02013;&#x000a0;Significant CAD</td><td>&#x02007;38 (19%)</td><td>&#x02007;&#x02007;&#x02007;4 (44%)</td><td>&#x02007;35 (18%)</td><td>&#x02007;&#x02007;&#x02007;3 (50%)</td><td>&#x02008;&#x02008;&#x02007;0.081</td></tr><tr><td>&#x02013;&#x000a0;TIA/CVA</td><td>&#x02007;31 (15%)</td><td>&#x02007;&#x02007;&#x02007;2 (22%)</td><td>&#x02007;30 (16%)</td><td>&#x02007;&#x02007;&#x02007;0 (0%)</td><td>&#x02008;&#x02008;&#x02007;0.593</td></tr><tr><td>&#x02013;&#x000a0;Hip/knee arthroplasty</td><td>&#x02007;18 (9%)</td><td>&#x02007;&#x02007;&#x02007;2 (22%)</td><td>&#x02007;17 (9%)</td><td>&#x02007;&#x02007;&#x02007;0 (0%)</td><td>&#x02008;&#x02008;&#x02007;1.000</td></tr><tr><td>&#x02013;&#x000a0;Trigger finger</td><td>&#x02007;&#x02007;7 (4%)</td><td>&#x02007;&#x02007;&#x02007;1 (11%)</td><td>&#x02007;&#x02007;6 (3%)</td><td>&#x02007;&#x02007;&#x02007;0 (0%)</td><td>&#x02008;&#x02008;&#x02007;1.000</td></tr><tr><td colspan="5"><italic>NYHA class</italic></td><td>&#x02008;&#x02008;&#x02007;0.955</td></tr><tr><td>&#x02013;&#x000a0;Class&#x000a0;I</td><td>&#x02007;&#x02007;3 (2%)</td><td>&#x02007;&#x02007;&#x02007;0 (0%)</td><td>&#x02007;&#x02007;3 (2%)</td><td>&#x02007;&#x02007;&#x02007;0 (0%)</td><td/></tr><tr><td>&#x02013;&#x000a0;Class&#x000a0;II</td><td>&#x02007;92 (46%)</td><td>&#x02007;&#x02007;&#x02007;4 (44%)</td><td>&#x02007;89 (46%)</td><td>&#x02007;&#x02007;&#x02007;3 (50%)</td><td/></tr><tr><td>&#x02013;&#x000a0;Class&#x000a0;III</td><td>&#x02007;98 (49%)</td><td>&#x02007;&#x02007;&#x02007;5 (56%)</td><td>&#x02007;93 (48%)</td><td>&#x02007;&#x02007;&#x02007;3 (50%)</td><td/></tr><tr><td>&#x02013;&#x000a0;Class&#x000a0;IV</td><td>&#x02007;&#x02007;4 (2%)</td><td>&#x02007;&#x02007;&#x02007;0 (0%)</td><td>&#x02007;&#x02007;4 (2%)</td><td>&#x02007;&#x02007;&#x02007;0 (0%)</td><td/></tr><tr><td colspan="6"><italic>Echocardiography</italic></td></tr><tr><td>&#x02013;&#x000a0;LVEF (%)</td><td>&#x02007;60 [56&#x02013;64]</td><td>&#x02007;&#x02007;60 [56&#x02013;61]</td><td>&#x02007;60 [57&#x02013;64]</td><td>&#x02007;&#x02007;58 [54&#x02013;62]</td><td>&#x02008;&#x02008;&#x02007;0.469</td></tr><tr><td>&#x02013;&#x000a0;LVEDD (mm)</td><td>&#x02007;48 [44&#x02013;51]</td><td>&#x02007;&#x02007;44 [40&#x02013;51]</td><td>&#x02007;48 [44&#x02013;51]</td><td>&#x02007;&#x02007;43 [39&#x02013;50]</td><td>&#x02008;&#x02008;&#x02007;0.094</td></tr><tr><td>&#x02013;&#x000a0;LVIVSd (mm)</td><td>&#x02007;10 [9&#x02013;11]</td><td>&#x02007;&#x02007;12 [11&#x02013;15]</td><td>&#x02007;10 [9&#x02013;11]</td><td>&#x02007;&#x02007;15 [11&#x02013;17]</td><td><bold>&#x0003c;</bold>&#x0202f;<bold>0.001</bold></td></tr><tr><td>&#x02013;&#x000a0;LVPWd (mm)</td><td>&#x02007;&#x02007;9 [8&#x02013;10]</td><td>&#x02007;&#x02007;11 [10&#x02013;14]</td><td>&#x02007;&#x02007;9 [8&#x02013;10]</td><td>&#x02007;&#x02007;12 [10&#x02013;15]</td><td><bold>&#x02008;&#x02008;&#x02007;0.002</bold></td></tr><tr><td>&#x02013;&#x000a0;LVMI (g/m<sup>2</sup>)</td><td>&#x02007;81 [69&#x02013;96]</td><td>&#x02007;106 [90&#x02013;107]</td><td>&#x02007;80 [69&#x02013;94]</td><td>&#x02007;104 [83&#x02013;164]</td><td><bold>&#x02008;&#x02008;&#x02007;0.037</bold></td></tr><tr><td>&#x02013;&#x000a0;LAVI (ml/m<sup>2</sup>)</td><td>&#x02007;45 [36&#x02013;55]</td><td>&#x02007;&#x02007;54 [49&#x02013;72]</td><td>&#x02007;44 [34&#x02013;55]</td><td>&#x02007;&#x02007;53 [39&#x02013;76]</td><td>&#x02008;&#x02008;&#x02007;0.176</td></tr><tr><td>&#x02013;&#x000a0;e&#x02019;&#x000a0;septal (cm/s)</td><td>&#x02007;&#x02007;6.3 [5.1&#x02013;7.8]</td><td>&#x02007;&#x02007;&#x02007;5.3 [4.8&#x02013;5.8]</td><td>&#x02007;&#x02007;6.5 [5.1&#x02013;7.8]</td><td>&#x02007;&#x02007;&#x02007;5.4 [4.7&#x02013;10.6]</td><td>&#x02008;&#x02008;&#x02007;0.645</td></tr><tr><td>&#x02013;&#x000a0;e&#x02019;&#x000a0;lateral (cm/s)</td><td>&#x02007;&#x02007;8.6 [6.6&#x02013;10.5]</td><td>&#x02007;&#x02007;&#x02007;7.5 [5.9&#x02013;8.4]</td><td>&#x02007;&#x02007;8.6 [6.6&#x02013;10.7]</td><td>&#x02007;&#x02007;&#x02007;7.8 [6.4&#x02013;8.6]</td><td>&#x02008;&#x02008;&#x02007;0.442</td></tr><tr><td>&#x02013;&#x000a0;E/e&#x02019;&#x000a0;average</td><td>&#x02007;11.2 [9.2&#x02013;14.7]</td><td>&#x02007;&#x02007;12.6 [11.5&#x02013;13.6]</td><td>&#x02007;11.2 [9.1&#x02013;14.9]</td><td>&#x02007;&#x02007;11.9 [10.7&#x02013;13.6]</td><td>&#x02008;&#x02008;&#x02007;0.659</td></tr><tr><td>&#x02013;&#x000a0;Aortic valve stenosis</td><td>&#x02007;15 (7%)</td><td>&#x02007;&#x02007;&#x02007;0 (0%)</td><td>&#x02007;15 (8%)</td><td>&#x02007;&#x02007;&#x02007;0 (0%)</td><td>&#x02008;&#x02008;&#x02007;1.000</td></tr><tr><td colspan="6"><italic>Electrocardiography</italic></td></tr><tr><td>&#x02013;&#x000a0;PQ duration (ms)</td><td>172 [148&#x02013;192]</td><td>&#x02007;177 [177&#x02013;178]</td><td>172 [148&#x02013;192]</td><td>&#x02007;177 [176&#x02013;178]</td><td>&#x02008;&#x02008;&#x02007;0.610</td></tr><tr><td>&#x02013;&#x000a0;QRS duration (ms)</td><td>&#x02007;92 [84&#x02013;110]</td><td>&#x02007;&#x02007;88 [84&#x02013;148]</td><td>&#x02007;96 [84&#x02013;113]</td><td>&#x02007;&#x02007;88 [81&#x02013;156]</td><td>&#x02008;&#x02008;&#x02007;0.736</td></tr><tr><td>&#x02013;&#x000a0;Conduction delay</td><td>&#x02007;65 (32%)</td><td>&#x02007;&#x02007;&#x02007;3 (33%)</td><td>&#x02007;63 (33%)</td><td>&#x02007;&#x02007;&#x02007;2 (33%)</td><td>&#x02008;&#x02008;&#x02007;1.000</td></tr><tr><td>&#x02013;&#x000a0;Micro-voltage signals</td><td>&#x02007;22 (11%)</td><td>&#x02007;&#x02007;&#x02007;2 (22%)</td><td>&#x02007;20 (10%)</td><td>&#x02007;&#x02007;&#x02007;2 (33%)</td><td>&#x02008;&#x02008;&#x02007;0.145</td></tr><tr><td colspan="6"><italic>Laboratory testing</italic></td></tr><tr><td>&#x02013;&#x000a0;eGFR (ml/min per 1.73&#x0202f;m<sup>2</sup>)</td><td>&#x02007;59 [40&#x02013;73]</td><td>&#x02007;&#x02007;45 [39&#x02013;64]</td><td>&#x02007;58.8 [40.7&#x02013;72.7]</td><td>&#x02007;&#x02007;48.4 [39.4&#x02013;80.6]</td><td>&#x02008;&#x02008;&#x02007;0.902</td></tr><tr><td>&#x02013;&#x000a0;NT-proBNP (pg/ml)</td><td>546 [287&#x02013;1199]</td><td>1362 [896&#x02013;3154]</td><td>541 [271&#x02013;1180]</td><td>2258 [787&#x02013;6410]</td><td><bold>&#x02008;&#x02008;&#x02007;0.011</bold></td></tr><tr><td>&#x02013;&#x000a0;hsTnT (ng/l)</td><td>&#x02007;19 [14&#x02013;36]</td><td>&#x02007;&#x02007;47 [27&#x02013;123]</td><td>&#x02007;17 [13&#x02013;35]</td><td>&#x02007;&#x02007;47 [13&#x02013;252]</td><td>&#x02008;&#x02008;&#x02007;0.254</td></tr></tbody></table><table-wrap-foot><p>Data are presented as <italic>n</italic> (%), mean&#x0202f;&#x000b1;&#x02009;standard deviation or median [interquartile range]</p><p><italic>HFpEF</italic>&#x000a0;heart failure with preserved ejection fraction, <italic>ATTR-CM</italic>&#x000a0;transthyretin amyloid cardiomyopathy, <italic>CAD</italic>&#x000a0;coronary artery disease, <italic>TIA</italic>&#x000a0;transient ischaemic attack, <italic>CVA</italic>&#x000a0;cerebrovascular accident, <italic>NYHA</italic>&#x000a0;New York Heart Association, <italic>LVEF</italic>&#x000a0;left ventricular ejection fraction, <italic>LVEDD</italic>&#x000a0;left ventricular enddiastolic diameter, <italic>LVIVSd</italic>&#x000a0;left ventricular interventricular septum diameter, <italic>LVPWd</italic>&#x000a0;left ventricular posterior wall diameter, <italic>LVMI</italic>&#x000a0;left ventricular mass index, <italic>LAVI</italic>&#x000a0;left atrial volume index, <italic>eGFR</italic>&#x000a0;estimated glomerular filtration rate, <italic>NT-proBNP</italic>&#x000a0;N-terminal pro B&#x02013;type natriuretic peptide, <italic>hsTnT</italic>&#x000a0;high sensitive troponin&#x000a0;T</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Prevalence of transthyretin amyloid cardiomyopathy (<italic>ATTR-CM</italic>) in patients with heart failure with preserved ejection fraction (<italic>HFpEF</italic>). <italic>IVSd</italic>&#x000a0;interventricular septum diameter</p></caption><graphic xlink:href="12471_2025_1954_Fig2_HTML" id="d33e928"/></fig></p><p>Of the 6&#x000a0;patients diagnosed with ATTR-CM, all but 1&#x000a0;were male, resulting in a&#x000a0;significantly higher proportion of male patients compared with non-amyloid HFpEF patients (83% vs 35%; <italic>p</italic>&#x0202f;=&#x02009;0.024). Furthermore, echocardiographic LVWT was significantly higher in patients with ATTR-CM compared with non-amyloid HFpEF patients, with a&#x000a0;median interventricular septum diameter of 15&#x0202f;mm (IQR: 11&#x02013;17) and 10&#x0202f;mm (IQR: 9&#x02013;11), respectively (<italic>p</italic>&#x0202f;&#x0003c;&#x02009;0.001), and a&#x000a0;median posterior wall diameter of 12&#x0202f;mm (IQR: 10&#x02013;15) and 9&#x0202f;mm (IQR: 8&#x02013;10), respectively (<italic>p</italic>&#x0202f;=&#x02009;0.002) (Tab.&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Two ATTR-CM patients (33%; 95% confidence interval: 4&#x02013;78%) did not have increased LVWT (&#x02265;&#x0202f;12&#x0202f;mm). These&#x000a0;2&#x000a0;patients were in the less advanced National Amyloidosis Centre (NAC) prognostic stage&#x000a0;I [<xref ref-type="bibr" rid="CR19">19</xref>]. In contrast, 3&#x000a0;out of the 4&#x000a0;ATTR-CM patients with increased LVWT were diagnosed with the more advanced prognostic stages&#x000a0;II and&#x000a0;III. Moreover, the 2&#x000a0;patients were classified as New York Heart Association (NYHA) class&#x000a0;II, whereas all but 1&#x000a0;of the patients with increased LVWT were classified as NYHA class&#x000a0;III. Nonetheless, both ATTR-CM patients without increased LVWT exhibited other typical red flags indicative of transthyretin amyloidosis.</p><p>Considering typical red flags indicative of ATTR-CM, 81% of the entire HFpEF patient cohort showed &#x02265;&#x0202f;1&#x000a0;identifiable red flags. Even when atrial fibrillation&#x02014;commonly observed in HFpEF&#x02014;was excluded as a&#x000a0;red flag, 142 patients of the entire cohort (71%) still presented with &#x02265;&#x0202f;1 red flags for ATTR-CM. Carpal tunnel syndrome was significantly more prevalent in ATTR-CM patients than non-amyloid HFpEF patients (67% vs 10%; <italic>p</italic>&#x0202f;=&#x02009;0.002), and ATTR-CM patients had a&#x000a0;higher median number of typical red flags (3; IQR: 2&#x02013;4 vs&#x000a0;1; IQR: 1&#x02013;2; <italic>p</italic>&#x0202f;=&#x02009;0.001). The frequencies of other specific red flags or comorbidities did not differ significantly (Tab.&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec7"><title>Discussion</title><p>Current guidelines recommend active screening for ATTR-CM in HFpEF patients with unexplained LVWT &#x02265;&#x0202f;12&#x0202f;mm and &#x02265;&#x0202f;1 typical red flags for amyloid cardiomyopathy [<xref ref-type="bibr" rid="CR7">7</xref>]. In light of this directive, our study has several noteworthy findings.</p><p>First, we found an ATTR-CM prevalence of 3% in an unselected HFpEF cohort, which is lower than that previously reported [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. This can be attributed to the fact that previous studies primarily included HFpEF patients with LVWT &#x02265;&#x0202f;12&#x0202f;mm [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>], thereby selecting a&#x000a0;subgroup with a&#x000a0;higher ATTR-CM prevalence. The study by Healy et&#x000a0;al. is one of only 2&#x000a0;studies that included HFpEF patients without explicitly increased wall thickness&#x000a0;[<xref ref-type="bibr" rid="CR20">20</xref>]. However, even in their cohort, 62% of the patients had LVWT &#x02265;&#x0202f;12&#x0202f;mm (median: 12&#x0202f;mm). The other study, by Devesa et&#x000a0;al., included hospitalised HFpEF patients with LVWT &#x0003c;&#x0202f;12&#x0202f;mm and reported an ATTR-CM prevalence of 5% [<xref ref-type="bibr" rid="CR5">5</xref>]. In our outpatient clinic, we included both HFpEF patients with and without LV hypertrophy but found an even lower ATTR-CM prevalence. This may be partly explained by the fact that 64% of our patients were female, whereas ATTR-CM is known to be more common in men [<xref ref-type="bibr" rid="CR21">21</xref>]. Initially, there was concern that female patients with ATTR-CM are underdiagnosed [<xref ref-type="bibr" rid="CR21">21</xref>], but our findings do not support this hypothesis. Despite screening a&#x000a0;large proportion of women, we identified very few cases of ATTR-CM. The high representation of female patients in our HFpEF cohort may therefore contribute to the low ATTR-CM prevalence observed.</p><p>Second, we identified 2 ATTR-CM patients (33%) without increased LVWT, who were in an early disease stage, as shown by their NAC prognostic stage and NYHA class. This supports the concept that cardiac uptake on bone scintigraphy serves as an indicator of ATTR-CM presence rather than amyloid fibril quantity and may thus identify ATTR-CM before clinically evident LV hypertrophy [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. If we had followed the current guidelines, these patients would have been overlooked or diagnosed at a&#x000a0;later disease stage&#x000a0;[<xref ref-type="bibr" rid="CR7">7</xref>]. Consequently, to facilitate early ATTR-CM diagnosis, it may be necessary to broaden the scope beyond patients with increased LVWT and consider other patient groups as well.</p><p>Currently, there is a&#x000a0;strong focus on using HFpEF patients as a&#x000a0;screening group for ATTR-CM [<xref ref-type="bibr" rid="CR7">7</xref>]. However, it is well established that over half of the ATTR-CM patients have a&#x000a0;reduced or mildly reduced LVEF&#x000a0;[<xref ref-type="bibr" rid="CR22">22</xref>]. This underscores that ATTR-CM can manifest across various cardiology subgroups, highlighting the urgent need for diagnostic indicators beyond echocardiography.</p><p>Last, we observed a&#x000a0;high prevalence of typical red flags for ATTR-CM in all HFpEF patients. Specifically, 81% of all HFpEF patients exhibited &#x02265;&#x0202f;1&#x000a0;red flags indicative of ATTR-CM. These findings highlight the diagnostic challenge for ATTR-CM, particularly in early disease stages. Routine bone scintigraphy in an unselected HFpEF population remains controversial due to the low prevalence of ATTR-CM in this group and the significant number of scans required. Therefore, we do not recommend standardised screening for ATTR-CM in all HFpEF patients but emphasise the urgent need for more specific ATTR-CM indicators beyond the currently described red flags and echocardiographic parameters. Meanwhile, targeted screening of HFpEF patients using existing screening tools may be a&#x000a0;practical approach in clinical practice [<xref ref-type="bibr" rid="CR13">13</xref>], as screening remains essential, particularly with the increasing number of treatment options available, even for patients in advanced disease stages [<xref ref-type="bibr" rid="CR23">23</xref>].</p><sec id="Sec8"><title>Study limitations</title><p>Our results may be affected by selection bias as the entire patient cohort was predominantly referred by cardiologists, with only a&#x000a0;small proportion referred by general practitioners. However, our hospital functions as both a&#x000a0;regional and university hospital, catering to a&#x000a0;diverse patient population representative of the local community. We believe our cohort broadly reflects the HFpEF population, as all patients suspected of HFpEF are evaluated systematically, irrespective of LVWT or ATTR-CM&#x02013;related red flags. Nonetheless, we acknowledge that the specialised nature of our HFpEF clinic and the diagnostic expertise of referring cardiologists may introduce a&#x000a0;degree of pre-selection bias, potentially impacting the ATTR-CM prevalence. Moreover, the high proportion of female patients in our cohort may have contributed to the low prevalence of ATTR-CM observed.</p><p>Furthermore, the decision of 2&#x000a0;patients to decline further evaluation for ATTR-CM following inconclusive bone scintigraphy may have influenced the ATTR-CM prevalence in our cohort, particularly given its already low rate. Nonetheless, we believe that the clinical relevance of these 2&#x000a0;cases is limited considering the overall very low prevalence of ATTR-CM in an unselected HFpEF cohort. Therefore, we excluded these patients from further analyses.</p></sec></sec><sec id="Sec9"><title>Conclusion</title><p>This investigation revealed a&#x000a0;low prevalence of ATTR-CM (3%) in unselected cohort of 202 HFpEF patients. We identified 2&#x000a0;ATTR-CM patients (33%) without increased LVWT, who presented at an earlier disease stage. Hence, relying solely on LVWT for ATTR-CM diagnosis may lead to delayed and/or missed diagnoses. Furthermore, 71% of all HFpEF patients had &#x02265;&#x0202f;1 red flags indicative of ATTR-CM, highlighting the need for more specific ATTR-CM indicators in this patient population.</p></sec></body><back><ack><sec id="FPar2"><title>Acknowledgements</title><p>The authors would like to thank the study patients for their efforts to participate in this research.</p></sec><sec id="FPar3"><title>Funding</title><p>Pfizer and AstraZeneca have provided research grants to the Maastricht University Medical Centre (no grant numbers available). Both companies had no influence on the study design, data collection, analyses, interpretation of the data or writing of the report.</p></sec></ack><notes id="FPar4" notes-type="COI-statement"><title>Conflict of interest</title><p>A.&#x000a0;Achten and C.&#x000a0;Knackstedt have received speaker&#x02019;s honoraria from Pfizer paid to the Maastricht University Medical Centre. C.&#x000a0;Knackstedt has also received consulting fees from Pfizer, BMS and Alnylam paid to the Maastricht University Medical Centre. V.P.M.&#x000a0;van Empel, J.&#x000a0;Weerts, S.&#x000a0;Mourmans, H.-P.&#x000a0;Brunner-La&#x000a0;Rocca and S.&#x000a0;Sanders-van&#x000a0;Wijk declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Magdi</surname><given-names>M</given-names></name><name><surname>Mostafa</surname><given-names>MR</given-names></name><name><surname>Abusnina</surname><given-names>W</given-names></name><etal/></person-group><article-title>A&#x000a0;systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction</article-title><source>Am J Cardiovasc Dis</source><year>2022</year><volume>12</volume><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">35873185</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Magdi M, Mostafa MR, Abusnina W, et al. A&#x000a0;systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. Am J Cardiovasc Dis. 2022;12:102&#x02013;11.<pub-id pub-id-type="pmid">35873185</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>AbouEzzeddine</surname><given-names>OF</given-names></name><name><surname>Davies</surname><given-names>DR</given-names></name><name><surname>Scott</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction</article-title><source>JAMA Cardiol</source><year>2021</year><volume>6</volume><fpage>1267</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2021.3070</pub-id><pub-id pub-id-type="pmid">34431962</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021;6:1267&#x02013;74.<pub-id pub-id-type="pmid">34431962</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-L&#x000f3;pez</surname><given-names>E</given-names></name><name><surname>Gallego-Delgado</surname><given-names>M</given-names></name><name><surname>Guzzo-Merello</surname><given-names>G</given-names></name><etal/></person-group><article-title>Wild-type transthyretin amyloidosis as a&#x000a0;cause of heart failure with preserved ejection fraction</article-title><source>Eur Heart J</source><year>2015</year><volume>36</volume><fpage>2585</fpage><lpage>2594</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv338</pub-id><pub-id pub-id-type="pmid">26224076</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Gonz&#x000e1;lez-L&#x000f3;pez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a&#x000a0;cause of heart failure with preserved ejection fraction. Eur Heart&#x000a0;J. 2015;36:2585&#x02013;94.<pub-id pub-id-type="pmid">26224076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Usman</surname><given-names>MS</given-names></name><name><surname>Anker</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A&#x000a0;scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension</article-title><source>Eur J Heart Fail</source><year>2023</year><volume>25</volume><fpage>936</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1002/ejhf.2894</pub-id><pub-id pub-id-type="pmid">37461163</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Anker SD, Usman MS, Anker MS, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A&#x000a0;scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail. 2023;25:936&#x02013;55.<pub-id pub-id-type="pmid">37461163</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Devesa</surname><given-names>A</given-names></name><name><surname>Camblor Blasco</surname><given-names>A</given-names></name><name><surname>Pello</surname><given-names>LAM</given-names></name><etal/></person-group><article-title>Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy</article-title><source>Esc Heart Fail</source><year>2021</year><volume>8</volume><fpage>2856</fpage><lpage>2865</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13360</pub-id><pub-id pub-id-type="pmid">33963812</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Devesa A, Camblor Blasco A, Pello LAM, et al. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. Esc Heart Fail. 2021;8:2856&#x02013;65.<pub-id pub-id-type="pmid">33963812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Pav&#x000ed;a</surname><given-names>P</given-names></name><name><surname>Garc&#x000ed;a-Pinilla</surname><given-names>JM</given-names></name><name><surname>Lozano-Bahamonde</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study</article-title><source>Rev Esp Cardiol</source><year>2024</year><volume>2024</volume><issue>8</issue><fpage>1885</fpage><lpage>585700240</lpage></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Garc&#x000ed;a-Pav&#x000ed;a P, Garc&#x000ed;a-Pinilla JM, Lozano-Bahamonde A, et al. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study. Rev Esp Cardiol. 2024;2024(8):1885&#x02013;585700240.</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Pavia</surname><given-names>P</given-names></name><name><surname>Rapezzi</surname><given-names>C</given-names></name><name><surname>Adler</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Diagnosis and treatment of cardiac amyloidosis. A&#x000a0;position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases</article-title><source>Eur J Heart Fail</source><year>2021</year><volume>23</volume><fpage>512</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1002/ejhf.2140</pub-id><pub-id pub-id-type="pmid">33826207</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A&#x000a0;position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23:512&#x02013;26.<pub-id pub-id-type="pmid">33826207</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Debonnaire</surname><given-names>P</given-names></name><name><surname>Claeys</surname><given-names>M</given-names></name><name><surname>De Smet</surname><given-names>M</given-names></name><etal/></person-group><article-title>Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications</article-title><source>Acta Cardiol</source><year>2022</year><volume>77</volume><fpage>791</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1080/00015385.2021.1976450</pub-id><pub-id pub-id-type="pmid">34565298</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Debonnaire P, Claeys M, De Smet M, et al. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications. Acta Cardiol. 2022;77:791&#x02013;804.<pub-id pub-id-type="pmid">34565298</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Achten</surname><given-names>A</given-names></name><name><surname>van Empel</surname><given-names>VPM</given-names></name><name><surname>Weerts</surname><given-names>J</given-names></name><etal/></person-group><article-title>Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years</article-title><source>Heart Vessels</source><year>2024</year><volume>39</volume><fpage>857</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1007/s00380-024-02408-3</pub-id><pub-id pub-id-type="pmid">38710807</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Achten A, van Empel VPM, Weerts J, et al. Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years. Heart Vessels. 2024;39:857&#x02013;66.<pub-id pub-id-type="pmid">38710807</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Muller SA, Achten A, van der Meer MG, et al. Absence of an increased wall thickness does not rule out cardiac amyloidosis. Amyloid. 2024; 10.1080/13506129.2024.2348681</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Remior-P&#x000e9;rez</surname><given-names>P</given-names></name><name><surname>G&#x000f3;mez-Molina</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a-Rodr&#x000ed;guez</surname><given-names>D</given-names></name><etal/></person-group><article-title>Prevalence of Cardiac Amyloidosis Among Elderly Patients With Recent-Onset Atrial Fibrillation: The PREVAL-ATTR Study</article-title><source>Can J Cardiol</source><year>2025</year><volume>41</volume><fpage>167</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.cjca.2024.10.010</pub-id><pub-id pub-id-type="pmid">39424187</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Remior-P&#x000e9;rez P, G&#x000f3;mez-Molina M, Garc&#x000ed;a-Rodr&#x000ed;guez D, et al. Prevalence of Cardiac Amyloidosis Among Elderly Patients With Recent-Onset Atrial Fibrillation: The PREVAL-ATTR Study. Can J Cardiol. 2025;41:167&#x02013;77.<pub-id pub-id-type="pmid">39424187</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Arshad</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>YH</given-names></name><name><surname>Bhopalwala</surname><given-names>H</given-names></name><etal/></person-group><article-title>High Prevalence of Cardiac Amyloidosis in Clinically Significant Aortic Stenosis: A&#x000a0;Meta-Analysis</article-title><source>Cardiol Res</source><year>2022</year><volume>13</volume><fpage>357</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.14740/cr1436</pub-id><pub-id pub-id-type="pmid">36660066</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Arshad S, Goldberg YH, Bhopalwala H, et al. High Prevalence of Cardiac Amyloidosis in Clinically Significant Aortic Stenosis: A&#x000a0;Meta-Analysis. Cardiol Res. 2022;13:357&#x02013;71.<pub-id pub-id-type="pmid">36660066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Arana-Achaga</surname><given-names>X</given-names></name><name><surname>Goena-Vives</surname><given-names>C</given-names></name><name><surname>Villanueva-Benito</surname><given-names>I</given-names></name><etal/></person-group><article-title>Development and Validation of a&#x000a0;Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo</article-title><source>JACC Cardiovasc Imaging</source><year>2023</year><volume>16</volume><fpage>1567</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2023.05.002</pub-id><pub-id pub-id-type="pmid">37389511</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Arana-Achaga X, Goena-Vives C, Villanueva-Benito I, et al. Development and Validation of a&#x000a0;Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo. JACC Cardiovasc Imaging. 2023;16:1567&#x02013;80.<pub-id pub-id-type="pmid">37389511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Brito</surname><given-names>D</given-names></name><name><surname>Albrecht</surname><given-names>FC</given-names></name><name><surname>de Arenaza</surname><given-names>DP</given-names></name><etal/></person-group><article-title>World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)</article-title><source>gh</source><year>2023</year><volume>18</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.5334/gh.1262</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Brito D, Albrecht FC, de Arenaza DP, et al. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). gh. 2023;18:59.</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="book"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>WHO methods and data sources for country-level causes of death 2000&#x02013;2019</source><year>2020</year><publisher-name>Global Health Estimates Technical Paper WHO/DDI/DNA/GHE/20202</publisher-name></element-citation><mixed-citation id="mc-CR15" publication-type="book">World Health Organization. WHO methods and data sources for country-level causes of death 2000&#x02013;2019. Global Health Estimates Technical Paper WHO/DDI/DNA/GHE/20202; 2020.</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Debonnaire</surname><given-names>P</given-names></name><name><surname>Claeys</surname><given-names>M</given-names></name><name><surname>De Paepe</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients: Results of the CASS Study</article-title><source>Jacc Cardiooncol</source><year>2023</year><volume>5</volume><fpage>836</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/j.jaccao.2023.05.012</pub-id><pub-id pub-id-type="pmid">38204999</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Debonnaire P, Claeys M, De Paepe P, et al. Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients: Results of the CASS Study. Jacc Cardiooncol. 2023;5:836&#x02013;8.<pub-id pub-id-type="pmid">38204999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Alvarez</surname><given-names>J</given-names></name><name><surname>Teruya</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?</article-title><source>Amyloid</source><year>2017</year><volume>24</volume><fpage>226</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1080/13506129.2017.1375908</pub-id><pub-id pub-id-type="pmid">28906148</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Rubin J, Alvarez J, Teruya S, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid. 2017;24:226&#x02013;30.<pub-id pub-id-type="pmid">28906148</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Musikantow</surname><given-names>DR</given-names></name><name><surname>Pugliese</surname><given-names>DN</given-names></name><etal/></person-group><article-title>Chest-Wall Adipose Tissue Excisional Biopsy During Pacemaker or Defibrillator Implantation: New Technique to Diagnose Amyloidosis</article-title><source>J Am Coll Cardiol</source><year>2022</year><volume>80</volume><fpage>93</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2022.05.002</pub-id><pub-id pub-id-type="pmid">35772920</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Zhang C, Musikantow DR, Pugliese DN, et al. Chest-Wall Adipose Tissue Excisional Biopsy During Pacemaker or Defibrillator Implantation: New Technique to Diagnose Amyloidosis. J&#x000a0;Am Coll Cardiol. 2022;80:93&#x02013;4.<pub-id pub-id-type="pmid">35772920</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Gillmore</surname><given-names>JD</given-names></name><name><surname>Damy</surname><given-names>T</given-names></name><name><surname>Fontana</surname><given-names>M</given-names></name><etal/></person-group><article-title>A&#x000a0;new staging system for cardiac transthyretin amyloidosis</article-title><source>Eur Heart J</source><year>2018</year><volume>39</volume><fpage>2799</fpage><lpage>2806</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx589</pub-id><pub-id pub-id-type="pmid">29048471</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gillmore JD, Damy T, Fontana M, et al. A&#x000a0;new staging system for cardiac transthyretin amyloidosis. Eur Heart&#x000a0;J. 2018;39:2799&#x02013;806.<pub-id pub-id-type="pmid">29048471</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Healy</surname><given-names>L</given-names></name><name><surname>Giblin</surname><given-names>G</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction</article-title><source>Esc Heart Fail</source><year>2024</year><pub-id pub-id-type="doi">10.1002/ehf2.15112</pub-id><pub-id pub-id-type="pmid">39508367</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Healy L, Giblin G, Gray A, et al. Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction. Esc Heart Fail. 2024; 10.1002/ehf2.15112.<pub-id pub-id-type="pmid">39508367</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Bruno</surname><given-names>M</given-names></name><name><surname>Casta&#x000f1;o</surname><given-names>A</given-names></name><name><surname>Burton</surname><given-names>A</given-names></name><name><surname>Grodin</surname><given-names>JL</given-names></name></person-group><article-title>Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges</article-title><source>Heart Fail Rev</source><year>2021</year><volume>26</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s10741-020-10010-8</pub-id><pub-id pub-id-type="pmid">32794090</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Bruno M, Casta&#x000f1;o A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Fail Rev. 2021;26:35&#x02013;45.<pub-id pub-id-type="pmid">32794090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Achten</surname><given-names>A</given-names></name><name><surname>Muller</surname><given-names>SA</given-names></name><name><surname>Wijk</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction</article-title><source>Ann Med</source><year>2024</year><volume>56</volume><fpage>2418965</fpage><pub-id pub-id-type="doi">10.1080/07853890.2024.2418965</pub-id><pub-id pub-id-type="pmid">39460551</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Achten A, Muller SA, Wijk SS, et al. Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction. Ann Med. 2024;56:2418965.<pub-id pub-id-type="pmid">39460551</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Pavia</surname><given-names>P</given-names></name></person-group><article-title>Aus dem Siepen F, Donal E, et&#x000a0;al. Phase&#x000a0;1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><fpage>239</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2303765</pub-id><pub-id pub-id-type="pmid">37212440</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Garcia-Pavia P. Aus dem Siepen F, Donal E, et&#x000a0;al. Phase&#x000a0;1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N&#x000a0;Engl J Med. 2023;389:239&#x02013;50.<pub-id pub-id-type="pmid">37212440</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>